Alessandro Arrigo Andrea Saladino Emanuela Aragona Stefano Mercuri Ugo Introini Francesco Bandello Maurizio Battaglia Parodi
10.1155/2021/5516981
Biomed Res Int
2021 May 24;2021:5516981.
CC BY
https://pubmed.ncbi.nlm.nih.gov/34124243/
Choroidal Neovascularization / drug therapy Macular Degeneration / drug therapy Ranibizumab / administration & dosage Receptors, Vascular Endothelial Growth Factor / administration & dosage Recombinant Fusion Proteins / administration & dosage Vascular Endothelial Growth Factor A / antagonists & inhibitors
Choroidal Neovascularization / drug therapy Macular Degeneration / drug therapy Ranibizumab / administration & dosage Receptors, Vascular Endothelial Growth Factor / administration & dosage Recombinant Fusion Proteins / administration & dosage Vascular Endothelial Growth Factor A / antagonists & inhibitors Clinical Trial Aged Aged, 80 and over Choroidal Neovascularization / classification Choroidal Neovascularization / pathology Choroidal Neovascularization / physiopathology Female Follow-Up Studies Humans Intravitreal Injections Macular Degeneration / pathology Macular Degeneration / physiopathology Male Recombinant Fusion Proteins VEGFA protein, human Vascular Endothelial Growth Factor A aflibercept Receptors, Vascular Endothelial Growth Factor Ranibizumab
PMC8169263
34124243
Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
2021